Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

This publication has 42 references indexed in Scilit:

• Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose
  Circulation, 2008
• Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome
  The American Journal of Cardiology, 2008
• Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
  Journal of Thrombosis and Haemostasis, 2007
• Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
  New England Journal of Medicine, 2007
• Renin-angiotensin-aldosterone system polymorphisms: a role or a hole in occurrence and long-term prognosis of acute myocardial infarction at young age
  BMC Medical Genetics, 2007
• Benefit of a 600-mg Loading Dose of Clopidogrel on Platelet Reactivity and Clinical Outcomes in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Coronary Stenting
  Journal of the American College of Cardiology, 2006
• INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450
  Drug Metabolism and Disposition, 2006
• Clopidogrel for Coronary Stenting
  Circulation, 2003
• P2Y12, a New Platelet ADP Receptor, Target of Clopidogrel
  Biochemical and Biophysical Research Communications, 2001
• Increased Plasma Levels of a Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial Infarction
  New England Journal of Medicine, 1985